AML patients ≥70 Achieve 60% Estimated Survival with UCB HCT

In this single-center retrospective study of 22 transplant recipients 70 years and older, 10 patients undergoing umbilical cord blood (UCB) transplantation had an estimated 2-year overall survival of 60%. Patients had myelodysplastic syndrome (MDS) and acute myelogenous leukemia (AML) with intermediate risk and most had HCT-CI scores of 0-2. The researchers noted that outcomes in the UCB cohort were similar to patients ≥70 years receiving HLA full-matched sibling donor transplantation (n=9) and a historical cohort of 60 patients between 60-69 years of age undergoing UCB transplantation. They conclude “UCB transplantation is feasible in selected AML/MDS patients ≥70 years.”

Sandhu KS, et al. Biol Blood Marrow Transplant

Related Resources